



PATENT APPLICATION Our File No.: 20050022.ORI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : Colin M. Casimir

: May 2, 2005

S.N. :

10/520,745 レ

: Art Unit unknown

Filed :

January 7, 2005

For

METHODS OF MAKING VIRAL PARTICLES HAVING

A MODIFIED CELL BINDING ACTIVITY AND

USES THEREOF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

Applicant(s) herein make available to the Patent and Trademark Office a copy of Form PTO-1449 which lists the following document(s), copies of which are enclosed. This Information Disclosure Statement is being filed in accordance with the following provision(s):

- [] 37 CFR 1.97(b)(1) Within three months of the filing date of the national application. No fee is required.
- [] 37 CFR 1.97(b)(2) Within three months of the date of entry of the national stage as set forth in § 1.491 in the international application. No fee is required.
- [X] 37 CFR 1.97(b)(3) Before the mailing date of a first Office Action on the merits. No fee is required.
- [] 37 CFR 1.97(c) After the periods specified in 37 CFR 1.97(b), but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.

- [] The undersigned hereby certifies that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or
- [] The undersigned hereby certifies that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; or
- [] Enclosed is a check in the amount of \$200.00 for the fee set forth in 37 CFR § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.
- [] 37 CFR 1.97(d) After the mailing date of either (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first, but before payment of the issue fee.
- [] Applicant(s) hereby petition the Commissioner of Patents and Trademarks to consider this information disclosure statement. Enclosed is a check in the amount of \$130.00 for the petition fee set forth in § 1.17(i)(1). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.

The listed documents are brought to the Examiner's attention because they are known to the applicant and/or the applicant's attorney and may be considered by the Examiner to be material to his/her examination. This listing should not be construed as representation that a search has been made or that no better art exists. No inference should be made that the documents are in fact material merely because they are referenced herein. Moreover, no representation is made that any brief descriptions of the references herein necessarily describe the most material aspects of the references. Further, by this listing, the applicant is not making any admission regarding the relative dates of the invention and listed disclosures.

The Examiner is requested to consider carefully the complete text of these documents in connection with the examination of the above-identified application in accordance with 37 CFR 1.104(a). It is requested that the documents listed on the attached Form PTO-1449 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. 1302.12), and that the Examiner initial and return a copy of the form to evidence consideration of the documents.

Dated: May 2, 2005.

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.

Compenseum

C. G. Mersereau

Attorney for Applicant(s) Registration No. 26,205 900 Second Avenue South

Suite 820

Minneapolis, MN 55402 Phone: 612-339-7461

CERTIFICATE OF MAILING

I hereby certify that the foregoing Information Disclosure Statement Under Rule 1.56, Form PTO-1449 and a copy of each cited reference to be filed in connection with application Serial No. 10/520,745 of inventors, Colin M. Casimir, filed January 7, 2005, for "METHODS OF MAKING VIRAL PARTICLES HAVING A MODIFIED CELL BINDING ACTIVITY AND USES THEREOF" are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 2, 2005.

Barbara L. Davis

Secretary to C. G. Mersereau

Darbara & Down

Date of Signature: May 2, 2005

(2-92) Sheet 1 of 8

MAY 0 5 &

Form PTO-1449

Document Number 20050022.ORI

Application Number 10/520,745

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant Colin M. Casimir

(Use several sheets if necessary)

Filing Date January 7, 2005 Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO
WO 97/12049	04/03/97	PCT			
WO 94/20621	09/15/94	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

 OTHER DOCUMENTS (Including Author, little, Date, Feltiment Fapers, Etc.)
Bittner et al, JOURNAL OF VIROLOGICAL METHODS, Specific Transduction of HIV-1 Envelope Expressing Cells by Retroviral Vectors Pseudotyped with Hybrid CD4/CXCR4 Receptors, Vol. 104, 2002, pp. 83-92
Jaing et al, JOURNAL OF VIROLOGY, Cell-Type-Specific Gene Transfer into Human Cells with Retroviral Vectors that Display Single-Chain Antibodies, Vol. 72, 1998, pp. 10148-10156
Lavillette et al, CURRENT OPINION IN BIOTECHNOLOGY, Retargeting Gene Delivery Using Surface-Engineered Retroviral Vector Particles, Vol. 12, 2001, pp. 461-466
Gollan et al, JOURNAL OF VIROLOGY, Redirecting Retroviral Tropism by Insertion of Short, Nondisruptive Peptide Ligands into Envelope, Vol. 76, 2002, pp. 3558-3563
Gollan et al, JOURNAL OF VIROLOGY, Selective Targeting and Inducible Destruction of Human Cancer Cells by Retroviruses with Envelope Proteins Bearing Short Peptide Ligands, Vol. 76, No. 7, 2002, pp. 3564-3569
Ager et al, HUMAN GENE THERAPY, Retroviral Display of Antibody Fragments; Interdomain Spacing Strongly Influences Vector Infectivity, Vol. 7, November 10, 1996, pp. 2157-2164
Bagnis et al, HUMAN GENE THERAPY, Retroviral Transfer of the $nlsLacZ$ Gene into Human $CD34^{\dagger}$ Cell Populations Into TF-1 Cells: Future Prospects in Gene Therapy, Vol. 5, November 1994, pp. 1325-1333

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP \Rightarrow 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Sheet 2 of 8

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Document Number 20050022.ORI

Application Number 10/520,745

Applicant

Colin M. Casimir

Filing Date January 7, 2005 Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
					-	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

Beradi et al, SCIENCE, Functional Isolation and Characterization of Human Hematopoietic Stem Cells, Vol. 267, No. 5194, January 6, 1995, pp. 104-108
Bodem et al, STEM CELLS, Regulation of Gene Expression by Human Foamy Virus and Potentials of Foamy Viral Vectors, Vol. 15, Suppl. 1, 1997, pp. 141-147
Cadd et al, BIOESSAYS, Budding of Enveloped Viruses from the Plasma Membrane, Vol. 19, No. 11, July 8, 1997, pp. 993-1000
Cosman et al, BEHRING INSTITUTE MITT, Human Macrophage Colony Stimulating Factor (M-CSF): Alternate RNA Splicing Generates Three Different Proteins that are Expressed on the Cell Surface and Secreted, Vol. 83, 1988, pp. 15-26
Cosset and Russell, GENE THERAPY, Targeting Retrovirus Entry, Vol. 3, 1996, pp. 946-956
Cosset et al, JOURNAL OF VIROLOGY, Retroviral Retargeting by Envelopes Expressing an N-Terminal Binding Domain, Vol. 69, No. 10, 1995, pp. 6314-6322
Cosset et al, JOURNAL OF VIROLOGY, High-Titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum, Vol. 69, No. 12, 1995, pp. 7430-7436
Etienne-Julan et al, JOURNAL OF GENERAL VIROLOGY, The Efficiency of Cell Targeting by Recombinant Retroviruses Depends on the Nature of the Receptor and the Composition of the Artificial Cell-Virus Linker, Vol. 73, 1992, pp. 3251-3255
GenBank Accession Number NM 002545

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP a 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Sheet 3 of 8

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Document Number 20050022.ORI

Application Number 10/520,745

Applicant

Colin M. Casimir

Filing Date January 7, 2005 Group Art Unit Unknown

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
•							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

,	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)
	Garoff et al, MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, Virus Maturation by Budding, Vol. 62, No. 4, Dec. 1998, pp. 1171-1190
	Goud et al, VIROLOGY, Antibody-Mediated Binding of a Murine Ecotropic Moloney Retroviral Vector to Human Cells Allows Internalization But Not the Establishment of the Proviral State, Vol. 163, 1988, pp. 251-254
	Griffiths and Rottier, CELL BIOLOGY, Cell Biology of Viruses that Assemble Along the Biosynthetic Pathway, Vol. 3, 1992, pp. 367-381
	Grignani et al, CANCER RESEARCH, High-Efficiency Gene Transfer and Selection of Human Hematopoietic Progenitor Cells with a Hybrid EBV/Retroviral Vector Expressing the Green Fluorescence Protein, Vol. 58, January 1, 1998, pp. 14-19
	Hamel and Westphal, JOURNAL OF NEURO-ONCOLOGY, The Road Less Traveled: C-Kit and Stem Cell Factor, Vol. 35, 1997, pp. 327-333
	Han et al, PROC. NAT'L. ACAD. SCI. USA, Ligand-Directed Retroviral Targeting of Human Breast Cancer Cells, Vol. 92, October 1995, pp. 9747-9751
	Hatziioannou et al, JOURNAL OF VIROLOGY, Incorporation of Fowl Plague Virus Hemagglutinin into Murine Leukemia Virus Particles and Analysis of the Infectivity of the Pseudotyped Retroviruses, Vol. 72, No. 6, June 1998, pp. 5313-5317
	Hatziioannou et al, HUMAN GENE THERAPY, Retroviral Display of Functional Binding Domains Fused to the Amino Terminus of Influenza Hemagglutinin, Vol. 10, June 10, 1999, pp. 1533-1544

EXAMINER DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP \Rightarrow 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

(2-92) Sheet 4 of 8

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Document Number 20050022.ORI

Application Number 10/520,745

Applicant

Colin M. Casimir

Filing Date
January 7, 2005

Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		F	OREIGN PATENT DOCUMEN	TS		
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

 OTHER DOCUMENTS (Including Author, little, Bate, leftlinent lapels, Btc.)
 Hurt et al, JOURNAL OF BIOLOGICAL CHEMISTRY, Cell-Type Specific Targeting of the a_{sc} -Adrenoceptor, Vol. 275, No. 45, November 10, 2000, pp. 35424-35431
Kasahara et al, SCIENCE, Tissue-Specific Targeting of Retroviral Vectors Through Ligand-Receptor Interactions, Vol. 266, 1994, pp. 1373-1376
Kinsella and Nolan, HUMAN GENE THERAPY, CEpisomal Vectors Rapidly and Stably Produce High-Titer Recombinant Retrovirus, Vol. 7, August 1, 1996, pp. 1405-1413
Kitamura et al, JOURNAL OF CELLULAR PHYSIOLOGY, Establishment and Characterization of a Unique Human Cell Line That Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin, Vol. 140, 1989, pp. 323-334
Lee et al, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Transcriptional and ERK1/2-Dependent Synergistic Upregulation of p21 ^{cip1/waf1} Associated with Steel Factor synergy in M07e, Vol. 280, 2001, pp. 675-683
Lee et al, SCIENCE, Mast Cells: A Cellular Link Between Autoantibodies and Inflammatory Arthritis, Vol. 297, September 6, 2002, pp. 1689-1692
Lyman et al, ONCOGENE, Identification of Soluble and Membrane-Bound Isoforms of the Murine flt3 Ligand Generated by Alternative Splicing of mRNAs, Vol. 10, 1995, pp. 149-157
Marin et al, JOURNAL OF VIROLOGY, Targeted Infection of Human Cells Via Major Histocompatibility Complex Class I Molecules by Moloney Murine Leukemia Virus-Derived Viruses Displaying Single-Chain Antibody Fragment-Envelope Fusion Proteins, Vol. 70, No. 5, May 1996, pp. 2957-2962

EXAMINER DATE CONSIDERED	EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP \Rightarrow 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Sheet 5 of 8

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

(2-92)

Document Number 20050022.ORI

Application Number 10/520,745

Applicant

Colin M. Casimir

Filing Date January 7, 2005 Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		F	OREIGN PATENT DOCUMENT	rs		
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)
Matano et al, JOURNAL OF GENERAL VIROLOGY, Targeted Infection of a Retrovirus Bearing a CD4-Env Chimera into Human Cells Expressing Human Immunodeficiency Virus Type 1, Vol. 76, 1995, pp. 3165-3169
Miyazawa et al, BLOOD, Membrane-Bound Steel Factor Induces More Persistent Tyrosine Kinase Activation and Longer Life Span of c-kit Gene-Encoded Protein Than Its Soluble Form, Vol. 85, No. 3, February 1, 1995, pp. 641-649
Morganstern and Land, NUCLEIC ACIDS RESEARCH, Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors with Multiple Drug Selection Markers and a Complementary Helper-free Packaging Cell Line, Vol. 18, No. 12, 1990, pp. 3587-3596
Neda et al, JOURNAL OF BIOLOGICAL CHEMISTRY, Chemical Modification of an Ecotropic Murine Leukemia virus Results in Redirection of Its Target Cell Specificity, Vol. 226, 1991, pp. 14143-14149
Pickard et al, JOURNAL OF NEUROSCIENCE, Developmental Changes in Synaptic AMPA and NMDA Receptor Distribution and AMPA Receptor Subunit Composition in Living Hippocampal Neurons, Vol. 20, November 1, 2000, pp. 7922-7931
Roux et al, PROC. NATL. ACAD. SCI. USA, A Versatile and Potentially General Approach to the Targeting of Specific Cell types by Retroviruses: Application to the Infection of Human Cells by Means of Major Histocompatibility complex Class I and Class II Antigens by Mouse Ecotropic Murine Leukemia Virus-Derived Viruses, Vol. 86, December 1989, pp. 9079-9083
Russell et al, NUCLEIC ACIDS RESEARCH, Retroviral Vectors Displaying Functional Antibody Fragments, Vol. 21, No. 5, 1993, pp. 1081-1085

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP \Rightarrow 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

(2-92)Sheet 6 of 8

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Document Number 20050022.ORI

Application Number 10/520,745

Applicant

Colin M. Casimir

Filing Date January 7, 2005 Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINI INITIA		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		F	OREIGN PATENT DOCUMEN	TS		
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO

 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)
Schnierle et al, GENE THERAPY, Expression of Chimeric Envelope Proteins in Helper Cell Lines and Integration into Moloney Murine Leukemia Virus Particles, Vol. 3, 1996, pp. 334-342
Sehgal et al, GENE THERAPY, Retroviral Transduction of Quiescent Haematopoietic Cells Using a Packaging Cell Line Expressing the Membrane- Bound Form of Stem Cell Factor, Vol. 6, 1999, pp. 1084-1091
Seigneurin et al, EXP. HERMATOL., Human Chronic Myeloid Leukemic Cell Line with Positive Philadelphia Chromosome Exhibits Megakaryocytic and Erythroid Characteristics, Vol. 15, 1987, pp. 822-832
Sellar et al, NATURE GENETICS, OPCML at 11q25 is Epigenetically Inactivated and has Tumor-Suppressor Function in epithelial Ovarian Cancer, Vol. 34, No. 3, July 2003, pp. 337-343
Somia et al, PROC. NATL. ACAD. SCI. USA, Generation of Targeted Retroviral Vectors by Using Single-Chain Variable Fragment: An Approach to in vivo Gene Delivery, Vol. 92, August 1995, pp. 7570-7574
Strauss et al, TRENDS IN MICROBIOLOGY, Budding of Alphaviruses, Vol. 3, No. 9, September 1995, pp. 346-350
Thalmeier et al, BLOOD, Establishment of Two Permanent Human bone Marrow Stromal Cell Lines with Long-term Post Irradiation Feeder Capacity, Vol. 83, No. 7, April 1, 1994, pp. 1799-1807
Valsesia-Wittmann et al, JOURNAL OF VIROLOGY, Modifications in the Binding Domain of Avian Retrovirus Envelope Protein to Redirect the Host Range of Retroviral Vectors, Vol. 68, No. 7, July 1994, pp. 4609-4619

	 	· · · · · · · · · · · · · · · · · · ·
EXAMINER	DATE CONSIDERED	
DARGINER	DATE CONSTDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP > 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the

Sheet 7 of 8 Application Number Document Number

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

Form PTO-1449

(Use several sheets if necessary)

20050022.ORI

Applicant Colin M. Casimir

Filing Date January 7, 2005 Group Art Unit Unknown

10/520,745

U.S. PATENT DOCUMENTS

EXAMINER DOCUMENT NUMBER DATE	NAME CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
-------------------------------	------------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO
WO 92/00376	01/09/92	PCT			
WO 94/10323	05/11/94	PCT			
 WO 01/72336	10/04/01	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

Valsesia-Wittmann et al, JOURNAL OF VIROLOGY, Modifications in the Binding Domain of Avian Retrovirus Envelope Protein to Redirect the Host Range of Retroviral Vectors, Vol. 70, No. 3, March 1996, pp. 2059-2064
Abbate et al, ARCH VIROL, Host Cell Antigenic Profile Acquired by HIV-1 is a Marker of its Cellular Origin, Vol. 140, 1995, pp. 1849-1854
Arthur et al, SCIENCE, Cellular Proteins Bound to Immunodeficiency Viruses: Implications for Pathogenesis and Vaccines, Vol. 258, December 18, 1992, pp. 1935-1938
Avanzi et al, BRITISH JOURNAL OF HERMATOLOGY, Selective Growth Response to IL-3 of a Human Leukaemic Cell Line with Megakaryoblastic Features, Vol. 69, 1988, pp. 359-366
Fielding et al, BLOOD, Inverse Targeting of Retroviral Vectors: Selective Gene Transfer in a Mixed Population of Hematopoietic and Nonhematopoietic Cells, Vol. 91, No. 5, March 1, 1998, pp. 1802-1809
Hammarstedt et al, PROC NATL SCI USA, Minimal Exclusion of Plasma Membrane Proteins During Retroviral Envelope Formation, Vol., 97, No. 13, June 20, 2000, pp. 7527-7532

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP > 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

		12	_ ,	_
heet	8	of	8	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Document Number 20050022.ORI

Application Number 10/520,745

Applicant

Colin M. Casimir

Filing Date January 7, 2005 Group Art Unit Unknown

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ı	INITIAL				•		IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO
				•	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

l .		
	Maurice et al, BLOOD, Efficient Gene Delivery to Quiescent Interleukin-2-Dependent Cells by Murine Leukemia Viru-Derived Vectors Harboring IL-2 Chimeric Envelopes Glycoproteins, Vol. 94, No. 2, July 15, 1999, pp. 401-	
	Okada et al, GENE THERAPY, Gene Therapy Against an Experimental Glioma Us Adeno-Associated Virus Vectors, Vol. 3, 1996, pp. 957-964	in
	Pickl et al, JOURNAL OF VIROLOGY, Lipid Rafts and Pseudotyping, Vol. 75, 15, August 2001, pp. 7175-7183	No.
	Pizzato et al, GENE THERAPY, Evidence for Nonspecific Adsorbtion of Targe Retrovirus Vector Particles to Cells, Vol. 8, 2001, PP. 1088-1096	ted
	Schols et al, VIROLOGY, Presence of Class II Histocompatibility DR Protei on the Envelope of Human Immunodeficiency Virus Demonstrated by FACS Analysis, Vol. 189, 1992, pp. 374-376	ns
	Yajima et al, HUMAN GENE THERAPY, Retroviral Vector Targeting human Cells c-Kit-Stem Cell Factor Interaction, Vol. 9, April 10, 1998, pp. 779-787	Via

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP > 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.